# Venrock Healthcare Capital Partners

> Venrock Healthcare Capital Partners is a VC fund backing Biotechnology. See 105 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Palo Alto, United States
- Total investments: 105
- Last investment: Jul 2026
- Lead investor: 26%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/venrock/
- Website: https://www.venrockcp.com/

Venrock Healthcare Capital Partners is a fund dedicated to investing in publicly-held and privately-held healthcare companies. It leverages its venture expertise, rigorous data analysis, and long-term supportive orientation to support successful biotechnology companies within the public markets. The company is headquartered in Palo Alto,California with an office in New York, New York.

## Contacts

5 contacts available for Venrock Healthcare Capital Partners. Shizune tracks 1 team members at Venrock Healthcare Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/venrock-healthcare-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 55 | 52% |
| Health Care | 33 | 31% |
| Therapeutics | 23 | 22% |
| Medical | 18 | 17% |
| Pharmaceutical | 17 | 16% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 28 | 27% |
| Series B | 16 | 15% |
| Series C | 9 | 9% |
| Series A | 6 | 6% |
| Series D | 1 | 1% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 46 | 44% |
| France | 2 | 2% |
| Ireland | 2 | 2% |
| Switzerland | 2 | 2% |
| China | 1 | 1% |

9 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ken Greenberg | Partner | 2 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Entera Bio | Entera Bio is developing novel oral drugs by utilizing its proprietary cutting edge delivery technology This technology protects large molecules and peptides in the GI tract. Oral drug delivery is the most straight forward and user friendly approach to medical treatment. Entera Bio has key personnel with the relevant know how, experience andnetworks working together to enable rapid development of its products. The company has an experienced management team with more than 50 years of combined drug development experience. | $275M | Post-IPO Equity | Jul 27, 2026 |  |
| Mentari Therapeutics | Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine. | $200M | Private Equity | Jul 22, 2026 |  |
| Lycia Therapeutics | Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M | Series D | Jun 25, 2026 |  |
| Artiva Biotherapeutics | Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technologicalbarriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates. | $300M | Post-IPO Equity | May 08, 2026 |  |
| CellCentric | CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $220M | Series D | May 06, 2026 |  |
| Achieve Life Science | Achieve Life Science manufactures pharmaceutical products. The firm develops cytisine as a smoking cessation aid. | $180M | Post-IPO Equity | Apr 16, 2026 |  |
| ADCendo | ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment. | $75M | Series C | Apr 14, 2026 |  |
| Alto Neuroscience | Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $120M | Post-IPO Equity | Mar 16, 2026 |  |
| Relmada Therapeutics | Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor(NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.() | $160M | Post-IPO Equity | Mar 09, 2026 |  |
| Korro Bio | Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in proteinstructure and function across multiple tissues.In 2018, | $85M | Post-IPO Equity | Mar 09, 2026 |  |

10 of 105 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 35 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 27 deals together
- [TCG Crossover](https://shizune.co/investors/profile/tcg-crossover) — VC Fund, 27 deals together
- [Fairmount Funds Management](https://shizune.co/investors/profile/fairmount-funds-management) — VC Fund, 26 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 26 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 26 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Venrock Healthcare Capital Partners invest in?

Venrock Healthcare Capital Partners invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 105 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Venrock Healthcare Capital Partners?

Public channels for Venrock Healthcare Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Venrock Healthcare Capital Partners?

The team at Venrock Healthcare Capital Partners includes Ken Greenberg (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co